ESPRのチャート
ESPRの企業情報
| symbol | ESPR |
|---|---|
| 会社名 | Esperion Therapeutics Inc (New) （エスペリオン・セラピュ―ティクス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 エスペリオン・セラピューティクス（Esperion Therapeutics Inc.）は脂質管理会社である。同社は低密度リポタンパク質コレステロール（LDL-C）上昇患者の治療用の1日に1回の経口療法の開発・商業化に焦点を当てた後期の製薬会社である。標的とする作用機序を有するベムドエイド酸は、経口投与が可能な1日1回のアデノシン三リン酸（ATP） - クエン酸リアーゼ（ACL）阻害剤であり、コレステロール生合成を低下させ、LDL- LDL受容体を調節するが、筋肉関連の副作用の可能性が低下する。単独療法としてのベムドエ酸に加えて、同社は、認可された非スタチン系の経口LDL-C降下療法であるエゼチミブと一定用量の組み合わせで、ベムドエ酸を開発中である。 エスペリオン・セラピュ―ティクスは米国のバイオ医薬品メ―カ―。高コレステロ―ル血症及び、その他の心臓代謝リスクマ―カ―を有する患者の治療のため、低比重リポタンパクコレステロ―ル濃度を低下させる治療法の開発、商業化に従事。経口治療薬と小分子治療薬を開発する。本社はミシガン州。 Through scientific and clinical excellence, and a deep understanding of cholesterol biology, the experienced Lipid Management Team at Esperion is committed to developing new LDL-C lowering medicines that will make a substantial impact on reducing global cardiovascular disease, the leading cause of death around the world. |
| 本社所在地 | 3891 Ranchero Drive Suite 150 Ann Arbor MI 48108 USA |
| 代表者氏名 | Timothy M. Mayleben ティモシー・M・メレイベン |
| 代表者役職名 | President Chief Executive Officer Director 社長兼最高経営責任者（CEO） |
| 電話番号 | +1 734-887-3903 |
| 設立年月日 | 39448 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2013年 |
| 従業員数 | － |
| url | www.esperion.com |
| nasdaq_url | https://www.nasdaq.com/symbol/espr |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -177.55900 |
| 終値（lastsale） | 44.48 |
| 時価総額（marketcap） | 1192227464 |
| 時価総額 | 時価総額（百万ドル） 1219.299 |
| 売上高 | 売上高（百万ドル） 0.00000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 139.278 |
| 当期純利益 | 当期純利益（百万ドル） -174.97000 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Esperion Therapeutics Inc revenues was not reported. Net loss increased 10% to $91.9M. Higher net loss reflects Research and development increase of 9% to $80.5M (expense) General and administrative increase of 24% to $12.9M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$3.72 to -$3.44. |
ESPRのテクニカル分析
ESPRのニュース
Why SeaChange International Shares Are Trading Higher By 17%; Here Are 20 Stocks Moving Premarket 2023/04/06 12:05:45 Benzinga
Gainers Virgin Orbit Holdings, Inc. (NASDAQ: VORB ) jumped 25.6% to $0.2512 in pre-market trading. Virgin Orbit Communications shares jumped 34% on Wednesday after a Telegraph report suggested the company is working with lawyers to agree on an emergency cash injection of around $31 million. LumiraDx Limited (NASDAQ: LMDX ) gained 20% to $0.66 in pre-market trading after gaining around 8% on Wednesday. Liquid Media Group Ltd. (NASDAQ: YVR ) gained 18.1% to $0.17 in pre-market trading. SeaChange International, Inc. (NASDAQ: SEAC ) gained 17.1% to $0.48 in pre-market trading after the company reported a rise in Q4 earnings. Esperion Therapeutics, Inc. (NASDAQ: ESPR ) shares climbed 15.1% to $1.45 in pre-market trading after declining 8% on Wednesday. Esperion recently announced a $56.7 million registered direct offering with institutional investors. AMC Entertainment Holdings, Inc. (NYSE: AMC ) gained 12.8% to $4.57 in pre-market trading. AMC Entertainment 13G Filing showed Millennium Management reported a 5.3% passive stake in the company as of March 30, 2023.
Top 5 Health Care Stocks That Preparing To Pump This Quarter 2023/03/29 11:28:50 Benzinga
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock''s strength on days when prices go up to its strength on days when prices go down. When compared to a stock''s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the RSI is below 30. Here’s the latest list of major oversold players in this sector, having an RSI near or below 30. Esperion Therapeutics, Inc. (NASDAQ: ESPR ) Esperion announced a $56.7 million registered direct offering with institutional investors. The company’s stock has a 52-week low of $1.26 . RSI Value: 22.41 ESPR Price Action: Shares of Esperion Therapeutics jumped 4.8% to close at $1.76 on Tuesday. SELLAS Life Sciences Group, Inc. (NASDAQ: SLS ) SELLAS Life Sciences posted a FY22 loss of $2.13 … Full story available on Benzinga.com
Benzinga''s ''Stock Whisper'' Index: 5 Stocks Investors Are Secretly Monitoring But Not Talking About Yet 2023/03/18 20:36:26 Benzinga
Investors are on the hunt for undervalued, underfollowed and emerging stocks when it comes to spotting opportunities. Retail traders have countless methods at their disposal to uncover new information. For some, this may be overwhelming. Benzinga’s Stock Whisper Index uses a combination of proprietary data and pattern recognition to showcase five stocks each week that are just under the surface and warrant attention. The index layers editorial commentary to help make sense of why these stocks should be of interest and whether investors and casual readers should watch them. Here is a look at the Benzinga Stock Whisper Index for the week of March 16, 2023. Jounce Therapeutics (NASDAQ: JNCE ): Shares of Jounce are up over 70% in the last five days. The move comes after the company shared data from its Phase 2 trial of JTX-8064 and pimivalimab among patients with ovarian cancer. The company is looking for a partner on JTX-8064. The strong results could help the company secure a partner and be what investors are betting on.
Lipella, ThermoGenesis top healthcare gainers; Esperion, Paratek lead losers'' pack 2023/03/16 14:03:57 Seeking Alpha
Lipella Pharmaceuticals (LIPO) +48%. ThermoGenesis Holdings (THMO) +34%. Esperion Therapeutics (ESPR) -66%. Paratek Pharmaceuticals (PRTK) -18%.
Dow Falls 150 Points; US Jobless Claims Decline Last Week 2023/03/16 13:53:01 Benzinga
U.S. stocks traded lower this morning, with the Dow Jones dropping more than 150 points on Thursday. Following the market opening Thursday, the Dow traded down 0.50% to 31,713.71 while the NASDAQ fell 0.18% to 11,412.93. The S&P 500, also fell, dropping, 0.33% to 3,879.20. Check This Out: Top 5 Tech Stocks Which You''ll Regret Missing This Quarter Leading and Lagging Sectors Communication services shares rose by 0.1% on Thursday. Meanwhile, top gainers in the sector included iHuman Inc. (NYSE: IH ), up 3%, and CarGurus, Inc. (NASDAQ: CARG ), up 1%. In trading on Thursday, energy shares tumbled by 1.4%. Top Headline US initial jobless claims dropped by 20,000 from the prior week to 192,000 in the week ending March 11, compared to market expectations of 205,000. Equities Trading UP PureCycle Technologies, Inc. (NASDAQ: PCT ) shares shot up 33% to $6.36 after the company provided a Q4 2022 update. Shares of UiPath Inc. (NYSE: PATH ) got a boost, shooting 19% to $17.45 after the company reported better-than-expected Q4 results and issued strong revenue guidance.
It would be worthwhile to take a closer look at Esperion Therapeutics Inc. (ESPR) 2022/12/27 16:54:00 US Post News
The share price of Esperion Therapeutics Inc. (NASDAQ:ESPR) fell to $6.07 per share on Friday from $6.36. While Esperion Therapeutics Inc. has underperformed by -4.56%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ESPR rose by 12.83%, with highs and lows ranging from $8.87 to $3.28, […]
Esperion Therapeutics Inc. (ESPR) Has Strong Growth Prospects Through 2022 2022/12/14 15:00:00 Marketing Sentinel
Esperion Therapeutics Inc. (NASDAQ:ESPR) has a beta value of 0.23 and has seen 2.43 million shares traded in the last trading session. The company, currently valued at $501.03M, closed the last trade at $5.60 per share which meant it gained $0.23 on the day or 4.28% during that session. The ESPR stock price is -58.39% … Esperion Therapeutics Inc. (ESPR) Has Strong Growth Prospects Through 2022 Read More »
Observations on the Esperion Therapeutics Inc. (NASDAQ:ESPR) Growth Curve 2022/12/12 18:00:00 US Post News
Esperion Therapeutics Inc. (ESPR)’s stock has witnessed a price declined of -0.29% from the previous close with its current price standing at $5.07. Its current price is -42.78% under its 52-week high of $8.87 and 54.73% more than its 52-week low of $3.28. Based on the past 30-day period, the stock price is -42.90% below […]
Following Its 52-Week Low, Esperion Therapeutics Inc. (NASDAQ: ESPR)’S Share Price Rose 35.56% And Its YTD Numbers Rise 1.80% 2022/12/10 13:30:00 Marketing Sentinel
During the last session, Esperion Therapeutics Inc. (NASDAQ:ESPR)’s traded shares were 7.06 million, with the beta value of the company hitting 0.21. At the end of the trading day, the stock’s price was $5.09, reflecting an intraday loss of -17.64% or -$1.09. The 52-week high for the ESPR share is $8.87, that puts it down … Following Its 52-Week Low, Esperion Therapeutics Inc. (NASDAQ: ESPR)’S Share Price Rose 35.56% And Its YTD Numbers Rise 1.80% Read More »
2 Biotech Stocks Options Traders Love Today - Schaeffer''s Investment Research 2022/12/07 17:16:01 Schaeffers Investment Research
Prometheus Biosciences (RXDX) and Esperion Therapeutics (ESPR) are both making waves following drug updates
Flickering stocks: Esperion Therapeutics, Inc. (NASDAQ:ESPR -10.01%), TechnipFMC plc (NYSE:FTI 1.88%) 2021/10/26 00:22:28 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 The post Flickering stocks: Esperion Therapeutics, Inc. (NASDAQ:ESPR -10.01%), TechnipFMC plc (NYSE:FTI 1.88%) appeared first on Stocks Equity .
Analysts Expect Esperion Therapeutics, Inc. (NASDAQ:ESPR) to Post -$2.86 EPS 2021/10/25 23:26:41 Dakota Financial News
Wall Street brokerages forecast that Esperion Therapeutics, Inc. (NASDAQ:ESPR) will report ($2.86) earnings per share (EPS) for the current quarter, according to Zacks. Three analysts have made estimates for Esperion Therapeutics earnings. The lowest EPS estimate is ($3.05) and the highest is ($2.63). Esperion Therapeutics reported earnings of ($3.07) per share in the same quarter []
Zacks: Analysts Anticipate Esperion Therapeutics, Inc. (NASDAQ:ESPR) Will Announce Quarterly Sales of $12.31 Million 2021/10/25 23:26:41 Transcript Daily
Wall Street analysts expect Esperion Therapeutics, Inc. (NASDAQ:ESPR) to report sales of $12.31 million for the current fiscal quarter, Zacks Investment Research reports. Three analysts have issued estimates for Esperion Therapeutics earnings, with the highest sales estimate coming in at $13.00 million and the lowest estimate coming in at $11.23 million. Esperion Therapeutics posted sales []
SG Americas Securities LLC Cuts Holdings in Esperion Therapeutics, Inc. (NASDAQ:ESPR) 2021/10/23 09:26:41 Dakota Financial News
SG Americas Securities LLC lessened its stake in Esperion Therapeutics, Inc. (NASDAQ:ESPR) by 14.9% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 13,844 shares of the biopharmaceutical companys stock after selling 2,422 shares during the period. SG Americas []
Esperion Therapeutics (NASDAQ:ESPR) Downgraded by Credit Suisse Group to Neutral 2021/10/22 06:20:41 Dakota Financial News
Credit Suisse Group lowered shares of Esperion Therapeutics (NASDAQ:ESPR) from an outperform rating to a neutral rating in a report released on Monday, PriceTargets.com reports. The firm currently has $11.00 price target on the biopharmaceutical companys stock, down from their previous price target of $28.00. Several other equities analysts also recently issued reports on the []